# A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque

Study · id `cardio:ct-nct06305559` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06305559](<https://clinicaltrials.gov/study/NCT06305559>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06305559

Browse, organ or system: Heart; Metabolism  
Browse, condition area: Risk and prevention; Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 300 participants.

## Technical summary

Registry record NCT06305559. Randomized; quadruple masking; primary purpose prevention. Start 2024-05-16 (actual); primary completion 2027-11 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 300 participants (planned count; ClinicalTrials.gov record NCT06305559, source copy `cardio:ctgov-nct06305559-2026-04-09`, retrieved 2026-10-26)
- Started: 2024-05-16 (actual) (ClinicalTrials.gov record NCT06305559, source copy `cardio:ctgov-nct06305559-2026-04-09`, retrieved 2026-10-26)
- Primary completion: 2027-11 (anticipated) (ClinicalTrials.gov record NCT06305559, source copy `cardio:ctgov-nct06305559-2026-04-09`, retrieved 2026-10-26)
- Completion: 2028-02 (anticipated) (ClinicalTrials.gov record NCT06305559, source copy `cardio:ctgov-nct06305559-2026-04-09`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT06305559, source copy `cardio:ctgov-nct06305559-2026-04-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06305559-2026-04-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque
- Acronym: REMBRANDT
- Condition: Lipidemia
- Condition: Coronary Artery Disease
- Condition: Plaque, Atherosclerotic
- Intervention (Drug): obicetrapib 10 mg + ezetimibe 10 mg FDC daily
- Intervention (Other): Placebo
- Lead sponsor: NewAmsterdam Pharma
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry lists this organization as the lead sponsor: NewAmsterdam Pharma (`cardio:org-newamsterdam-pharma`)

## Provenance

Content hash: 6435eca96d3ab6d635836dd7bfb6fa684cd31577fc12491177404ca0e0d11bde
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
